To understand why the review matters, it helps to grasp what makes an AI system agentic in the first place. Most pathology AI deployed today is a fixed pipeline: an image goes in, a prediction comes out, and the model has no ability to change its own behavior at inference time. Agentic systems break that mold. They coordinate multiple components, including perception models that analyze images, large language models that reason over textual knowledge, external tools such as databases or specialized classifiers, and feedback loops that let the system revise its own intermediate conclusions. Crucially, the control flow is dynamic rather than predetermined. The system decides, moment by moment, which tool to call, which region of a slide to examine next, and when it has gathered enough evidence to render a judgment.

The authors organize this emerging field with an operational taxonomy built on three pillars: dynamic control flow, inference-time tool selection, and knowledge integration. This framework matters because the term agentic has become a marketing buzzword as much as a technical one, applied to everything from simple chatbot wrappers to genuinely autonomous multi-model pipelines. By defining agency in terms of what a system actually does at inference time, whether it selects its own tools, integrates new knowledge on the fly, and adapts its reasoning path, the review gives researchers and regulators a common vocabulary for evaluating claims. Under this taxonomy, the authors survey architectures and enabling technologies across the major application domains of computational pathology: diagnosis, prognosis, and therapeutic support.

The technical appeal of agentic designs is easy to see. A single static model trained to detect one cancer type in one organ struggles the moment it encounters an unusual case, a rare variant, or a question it was never trained to answer. An agentic system, in principle, could recognize the limits of its own competence, consult a reference knowledge base, dispatch a specialized sub-model for a second opinion, and synthesize the results into a coherent report, much as a pathologist might consult a colleague or the literature. Early prototypes demonstrate that this kind of flexible orchestration is feasible, and the review treats that feasibility as established. The perception components, the language models, and the orchestration layers all exist and can be wired together into functioning systems.

Feasibility, however, is where the good news ends, at least for now. The review’s central and most consequential finding is that agentic architectures have not yet demonstrated clinical benefit. The evidence base consists almost entirely of retrospective benchmarks and research prototypes, studies in which systems are tested on archived data rather than deployed in live diagnostic workflows. Retrospective performance, the authors emphasize, is a notoriously poor predictor of real-world clinical value. A model that achieves impressive accuracy on a curated test set may fail in unpredictable ways when confronted with the staining variability, scanning artifacts, and case mix of an actual hospital.

There is a deeper methodological problem lurking in the literature, and the review names it directly: reported gains are difficult to attribute to agentic organization itself. When a new agentic system outperforms an older one, is the improvement due to the clever orchestration, or simply to a stronger underlying vision model, more training data, or a larger inference budget that lets the system think longer? Because studies differ in backbone models, datasets, and computational resources, most published comparisons cannot isolate the contribution of agency. This is a familiar trap in AI research, where architectural novelty often gets credit for gains that actually come from scale. Until head-to-head comparisons are run with matched backbones, matched data, and matched compute, the field cannot honestly claim that agentic organization, as opposed to brute capability, is what delivers the benefit.

The review also catalogues the specific risks that agentic designs introduce on top of those inherent in any medical AI. Large language models can hallucinate, generating confident but false statements, and in a pathology context a hallucinated finding woven into a diagnostic report is a patient-safety hazard. Multi-component systems expand the attack surface for security threats, since each tool call and knowledge lookup is a potential point of failure or manipulation. Computational cost is another practical concern: agentic systems that invoke multiple models and iterative reasoning loops consume far more compute than a single forward pass through a classifier, which affects both latency and the economics of deployment. And workflow integration remains the perennial stumbling block for pathology AI, because a system that is accurate but awkward to use, or that disrupts how pathologists actually work, will simply go unused.

Regulatory and human factors add further layers of complexity. Dynamic systems whose behavior depends on inference-time decisions are harder to validate and lock down than fixed models, raising unresolved questions about how regulators should assess software that does not always do the same thing given the same input. The authors also point to patient preferences as a consideration that is often absent from technical papers but central to clinical adoption, alongside the non-negotiable requirement that pathologists retain meaningful oversight of any AI-assisted diagnosis. Notably, the review does not treat agentic AI as inevitable. It explicitly identifies conditions under which specialist non-agentic models remain preferable, a stance that cuts against the industry narrative that autonomy is always the goal. For a well-defined task such as detecting mitotic figures or grading a common tumor subtype, a narrow, validated, inexpensive model may simply be the better tool.

So what would it take for agentic pathology AI to earn clinical trust? The authors lay out a translation roadmap that reads as a checklist for the field. First, prioritize verifiable tasks, meaning applications where the correctness of the AI’s output can be objectively checked, rather than open-ended reasoning with no ground truth. Second, run matched comparisons that isolate the effect of agentic organization from confounds like model scale. Third, pursue prospective and external validation, testing systems on new cases, at new institutions, in real time, rather than re-splitting old datasets. Fourth, establish lifecycle governance, continuous monitoring and updating frameworks appropriate to systems that may behave differently over time as their components evolve. Finally, design interfaces that preserve pathologist oversight, keeping the human diagnostician in command rather than relegating them to rubber-stamping machine output.

The timing of this sober assessment is significant. Agentic AI is arguably the hottest concept in the technology sector, and medicine is under intense pressure to adopt it, with vendors promising autonomous diagnostic agents that could ease workforce shortages and accelerate care. This review, published open access and grounded in a systematic survey rather than promotional claims, offers a counterweight: a technically literate account that concedes the engineering achievements while insisting that the clinical evidence simply does not exist yet. For pathologists, hospital administrators, and regulators, the message is to distinguish enthusiasm from evidence. For researchers, it is a call to design the rigorous studies that could eventually justify deployment. Agentic systems may well reshape computational pathology, but as this analysis makes clear, the road from impressive demo to dependable diagnosis runs through prospective trials, honest comparisons, and governance structures that keep patients, and the pathologists who serve them, firmly in the loop.

Subject of Research: Agentic AI architectures for computational pathology and their translational challenges

Article Title: Agentic systems in computational pathology: architectures, evidence, and translational challenges

Article References: Lu, X., Li, Q., Gao, Y., Dong, W., Lyu, M., Ma, S., Li, J., Wu, Y., Cai, L., Zhang, T., Lyu, S., Liu, Z., Liu, H., & Luo, S. (2026). Agentic systems in computational pathology: architectures, evidence, and translational challenges. Journal of Translational Medicine, 24(1), Article 1111. https://doi.org/10.1186/s12967-026-08829-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08829-0

Keywords: agentic AI, computational pathology, digital pathology, whole-slide imaging, large language models, clinical validation, translational medicine, AI regulation, hallucination risk, diagnostic AI, prospective validation, pathologist oversight

The letter is a direct response to work by Saha and colleagues, who laid out a comprehensive translational framework covering data harmonization, explainability, federated learning, algorithmic bias, model drift, and regulatory readiness. The three correspondents are careful to praise much of that vision, and they specifically endorse the framework’s embrace of decision-curve analysis as a way to move model evaluation beyond the narrow metric of discrimination, which measures only how well a model separates patients who experience an outcome from those who do not. Discrimination, long the headline number in prediction studies, says nothing about what clinicians should actually do with a probability estimate. Decision-curve analysis was designed to fill that gap by estimating a quantity called net benefit across a range of threshold probabilities, effectively asking how many true positives a model captures at a given willingness to act, minus the harm caused by false positives weighted by their relative cost. It is an elegant piece of mathematics, and its adoption has been largely welcomed by methodologists who spent years warning that area under the receiver operating characteristic curve was being overinterpreted.

But elegance in a formula is not the same as validity at the bedside, and this is where the new letter sharpens its critique. Net benefit, the authors explain, is calculated across assumed threshold probabilities, which means it depends on three fragile conditions holding simultaneously. First, the model’s predicted risks must be sufficiently calibrated, meaning that when a model says a patient has a thirty percent chance of recurrence, roughly thirty percent of similar patients should actually recur. Second, the thresholds across which the curve is drawn must reflect real clinical choices, not arbitrary mathematical ranges. Third, the predictions must be available at the intended point of care, using variables that exist when the decision must actually be made. A model can display a favorable net-benefit curve despite poor calibration in a new population, unstable performance in clinically important subgroups, or reliance on variables that simply are not available when the oncologist needs an answer. The statistic, in other words, inherits every weakness of the model and every assumption of the analyst, and then presents the result as a single smooth curve that looks reassuringly quantitative.

The problem deepens when the threshold range itself is examined critically. A mathematically plausible sweep of threshold probabilities may include values that are clinically unrealistic, because they fail to reflect the genuine consequences of false-positive and false-negative decisions, the downstream capacity for confirmatory testing, patient preferences, or the existence of competing treatment options. In cancer care, where a flagged prediction might trigger a needle biopsy, additional imaging, treatment escalation, or years of intensified surveillance, each of which carries its own benefit and harm, the choice of threshold is a clinical and ethical judgment, not a plotting convention. The authors argue that decision-curve analysis should therefore be interpreted only after the target population, the prediction time point, the comparator strategies, the outcome horizon, and the clinically defensible thresholds have all been prespecified. Without that discipline, the curve becomes an exercise in retrospective storytelling, with analysts free to choose the window in which their model happens to look best.

What the correspondents propose in place of a single utility benchmark is a staged clinical-evidence pathway, a ladder that a cancer AI model must climb before its decision curve can be taken seriously. The first rung is analytical and predictive validity, established through transparent reporting, calibration assessment, internal validation, and external validation on datasets that are geographically and temporally distinct from the development data. This stage should follow TRIPOD + AI, the updated guidance for reporting clinical prediction models that use regression or machine-learning methods, published in the BMJ by Collins and colleagues in 2024. The second rung is where decision-curve analysis properly belongs: estimating potential net benefit against realistic alternatives, with uncertainty quantification and sensitivity analyses across prespecified thresholds rather than post hoc selections. Only after those two stages pass does the model earn the right to face the messier tests of real clinical environments.

The third rung takes the model out of the retrospective dataset entirely and into silent prospective validation, running within its intended clinical workflow without influencing care. This shadow phase exists to expose problems that historical data cannot reproduce: data latency, missing fields, distribution shift as the patient population changes, and plain implementation failures such as incompatible record systems or delayed result transmission. Many models that performed beautifully on archived data have stumbled here, and the letter’s authors argue that no net-benefit curve should be cited as evidence of clinical utility until these operational hazards have been observed and addressed. It is a humble but essential checkpoint, because the conditions under which a model was trained are never quite the conditions under which it must perform.

Fourth comes live early-stage evaluation, and this is where the correspondence widens its lens from the algorithm to the humans around it. What matters at this stage is not merely algorithmic accuracy but human-AI interaction: who receives the model’s output, how it changes decisions, whether clinicians can recognize incorrect recommendations, and whether automation bias, alert fatigue, or inequitable override patterns begin to emerge. Automation bias, the well-documented tendency of human experts to defer to machine suggestions even when the machine is wrong, is a particular hazard in high-volume oncology settings where time pressure makes a second opinion costly. The authors point to DECIDE-AI, the reporting guideline for early-stage clinical evaluation of AI-driven decision support systems, as the appropriate framework for this phase of testing. The fifth rung then asks the question that ultimately matters most: does AI-assisted care actually improve patient-relevant or process outcomes compared with current practice? Ideally this is tested with randomized or otherwise rigorous prospective designs, with CONSORT-AI, the extension of the CONSORT reporting guidelines for interventions involving artificial intelligence, guiding how such trials are reported.

The sixth and final rung extends beyond deployment day, which the authors insist is not the end of evaluation but the beginning of a monitoring obligation. Post-deployment surveillance should track subgroup performance, calibration drift, safety events, cybersecurity threats, and user behavior, against predefined criteria for recalibration, suspension, or retirement of the model. These lifecycle requirements align with the FUTURE-AI consensus, the international guideline for trustworthy and deployable healthcare AI published in the BMJ in 2025 by Lekadir and colleagues. The underlying philosophy is that clinical AI is not a static artifact that can be certified once and forgotten; it is a sociotechnical system whose performance erodes as populations, practices, and data streams evolve. A model that was safe and beneficial in 2026 may drift quietly into harm well before anyone notices, unless monitoring is built into the deployment from the start.

The oncology context gives this argument its urgency. Prediction models in cancer care may trigger invasive biopsies, additional imaging, treatment escalation, or surveillance regimens that create both benefit and harm, often in the same patient. Clinical utility cannot be inferred from a positive net-benefit curve alone, the authors write; it is demonstrated only when a well-calibrated, transportable model is usable by its intended clinicians, improves decisions relative to a credible comparator, benefits patients, and remains safe after deployment. Each clause in that sentence carries its own burden of proof, and none of them can be discharged by a statistical plot drawn from retrospective data. The letter does not diminish decision-curve analysis; rather, it relocates the tool to the rung where it belongs, as a valuable bridge between mathematical evaluation and clinical evaluation, and a strictly necessary but far from sufficient condition for trust.

The correspondence closes with an invitation rather than a rebuke. The framework proposed by Saha and colleagues, the authors note, is well positioned to incorporate this evidence ladder, and doing so would preserve decision-curve analysis as a valuable translational tool while clarifying that clinical utility is a property of the complete sociotechnical intervention, not the prediction model in isolation. As hospitals worldwide prepare to embed machine-learning systems into cancer diagnosis, staging, and treatment planning, the letter offers a sober benchmark for the field: the question is no longer whether a model produces an impressive curve, but whether the entire chain of evidence, from transparent reporting through silent validation, human interaction studies, comparative trials, and post-deployment monitoring, has been completed before the algorithm touches a patient’s care. In a discipline where the cost of a wrong prediction is measured in biopsies, toxic therapies, and missed cancers, the authors argue, that full chain is the only honest definition of utility.

Subject of Research: The role of decision-curve analysis in evaluating clinical artificial intelligence for oncology

Article Title: Decision-curve analysis should be a bridge, not an endpoint, for clinical artificial intelligence in oncology

Article References: Khalid, M., Sarfraz, M., & Javad, F. (2026). Decision-curve analysis should be a bridge, not an endpoint, for clinical artificial intelligence in oncology. Journal of Translational Medicine, 24(1), Article 1202. https://doi.org/10.1186/s12967-026-08775-x

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08775-x

Keywords: decision-curve analysis, clinical artificial intelligence, oncology, net benefit, model calibration, TRIPOD+AI, DECIDE-AI, CONSORT-AI, FUTURE-AI, prospective validation, machine learning, translational medicine